The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group
Abstract
Timed sequencing of cycles of induction chemotherapy in acute myeloid leukemia (AML) has been proposed as a way to achieve maximal leukemic cell kill through recruitment and synchronization of residual neoplastic cells. Furthermore, whether intensive induction therapy should be continued in the presence of profound myelosuppression is an important question. The Children's Cancer Group (CCG) conducted a prospective randomized trial in which 589 patients with AML were randomized at diagnosis to one of two induction approaches involving a 4-day cycle of five active chemotherapeutic agents, with the second cycle administered either 10 days after the first cycle, despite low or dropping blood counts (intensive timing), or 14 days or later from the beginning of the first cycle, depending on bone marrow status (standard timing). All patients achieving remission received a total of four cycles of induction therapy. They were then allocated to allogeneic bone marrow transplantation (BMT) if a compatible family donor was present or randomized to aggressive nonmyeloablative therapy or to myeloablative therapy with purged autologous BMT rescue. The three postremission arms remain coded. Induction success and median days to complete induction were similar for the 295 patients randomized to the intensive timing arm (75%, 99 days) compared with the 294 patients randomized to the standard timing arm (70%, 105 days; P = .18 for remission). However, a marked improvement in outcome was demonstrated in patients randomized to the intensive timing arm, with an actuarial event-free survival at 3 years of 42% +/- 7% (95% confidence interval [CI]) versus 27% +/- 6% for patients on the standard timing arm (P = .0005). Disease-free survival results at 3 years from the end of induction were superior for patients receiving intensively timed induction therapy (N = 211), 55% +/- 9% versus 37% +/- 9% for standard timing patients (N = 195, P = .0002), with a median follow-up from achieving remission of 28 months. Superior results were documented for patients receiving intensive timing irrespective of the postremission therapy to which they were allocated. Intensively timed induction therapy for patients with AML markedly improves event-free survival, even for patients undergoing myeloablative therapy with BMT rescue. Without controlling for the type of induction therapy received, results of various BMT studies in AML comparing different preparative regimens will be difficult to interpret.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-620 · Cited by 2,926
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Skipper, H. E., Schabel, F. M., & Wilcox, W. S. (1964) · PubMed · Cited by 904
Dose: A critical factor in cancer chemotherapy
Frei, E., & Canellos, G. P. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90472-6 · Cited by 839
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310226 · Cited by 556
Yeager, A. M., Kaizer, H., Santos, G. W., Saral, R., Colvin, O. M., Stuart, R. K., Braine, H. G., Burke, P. J., Ambinder, R. F., Burns, W. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198607173150301 · Cited by 431
THE NATURAL DURATION OF CANCER
Lazarus-Barlow, W. S., & Leeming, J. H. (1924) · BMJ · doi:10.1136/bmj.2.3320.266 · Cited by 427
Varying intensity of postremission therapy in acute myeloid leukemia
Cassileth, P., Lynch, E., Hines, J., Oken, M., Mazza, J., Bennett, J., McGlave, P., Edelstein, M., Harrington, D., & O'Connell, M. (1992) · Blood · doi:10.1182/blood.v79.8.1924.1924 · Cited by 296
Wolff, S. N., Herzig, R. H., Fay, J. W. J., Phillips, G. L., Lazarus, H. M., Flexner, J. M., Stein, R. S., Greer, J. P., Cooper, B., & Herzig, G. P. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1260 · Cited by 143
Cited by
Fröhling, S., Schlenk, R. F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2002) · Blood · doi:10.1182/blood-2002-05-1440 · Cited by 871
Womer, R. B., West, D. C., Krailo, M. D., Dickman, P. S., Pawel, B. R., Grier, H. E., Marcus, K., Sailer, S., Healey, J. H., Dormans, J. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5703 · Cited by 757
Rubnitz, J. E., Inaba, H., Dahl, G., Ribeiro, R. C., Bowman, W. P., Taub, J., Pounds, S., Razzouk, B. I., Lacayo, N. J., Cao, X., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70090-5 · Cited by 584
Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Meshinchi, S., Woods, W. G., Stirewalt, D. L., Sweetser, D. A., Buckley, J. D., Tjoa, T. K., Bernstein, I. D., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.1.89 · Cited by 518
Self-citation
Metadata
- Authors
- Woods, W., Kobrinsky, N., Buckley, J., Lee, J., Sanders, J., Neudorf, S., Gold, S., Barnard, D., DeSwarte, J., Dusenbery, K., Kalousek, D., Arthur, D., & Lange, B.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1996-06-15
- Volume
- 87
- Issue
- 12
- Pages
- 4979-4989
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4474461
- Cited by
- 329
- References
- 16
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. https://app.cochat.ai/papers/10.1182/blood.v87.12.4979.bloodjournal87124979
- The paper
- Woods, W., Kobrinsky, N., Buckley, J., Lee, J., Sanders, J., Neudorf, S., Gold, S., Barnard, D., DeSwarte, J., Dusenbery, K., Kalousek, D., Arthur, D., & Lange, B. (1996). Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. https://doi.org/10.1182/blood.v87.12.4979.bloodjournal87124979
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.